NASDAQ:MGTA Magenta Therapeutics (MGTA) Stock Forecast, Price & News $0.64 +0.01 (+1.59%) (As of 05/26/2023 03:59 PM ET) Add Compare Share Share Today's Range$0.62▼$0.6550-Day Range$0.62▼$0.8152-Week Range$0.32▼$2.24Volume126,400 shsAverage Volume1.25 million shsMarket Capitalization$38.82 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Magenta Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside212.5% Upside$2.00 Price TargetShort InterestHealthy0.86% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.82) to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.67 out of 5 starsMedical Sector91st out of 1,010 stocksPharmaceutical Preparations Industry33rd out of 494 stocks 3.0 Analyst's Opinion Consensus RatingMagenta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Magenta Therapeutics has a forecasted upside of 212.5% from its current price of $0.64.Amount of Analyst CoverageMagenta Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.86% of the float of Magenta Therapeutics has been sold short.Short Interest Ratio / Days to CoverMagenta Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Magenta Therapeutics has recently decreased by 56.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMagenta Therapeutics does not currently pay a dividend.Dividend GrowthMagenta Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMagenta Therapeutics has received a 74.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Magenta Therapeutics is -0.84. Previous Next 3.0 News and Social Media Coverage News SentimentMagenta Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Magenta Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Magenta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.56% of the stock of Magenta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.68% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Magenta Therapeutics are expected to grow in the coming year, from ($0.82) to $0.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Magenta Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Magenta Therapeutics is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMagenta Therapeutics has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Magenta Therapeutics (NASDAQ:MGTA) StockMagenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA.Read More Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTA Stock News HeadlinesMay 11, 2023 | marketwatch.comMoore Kuehn Encourages MGTA, HSKA, RUTH and SYNH Investors to Contact Law FirmMay 10, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Magenta Therapeutics, Inc. (NASDAQ:MGTA) Decreased by WedbushMay 29, 2023 | Behind the Markets (Ad)WARNING TO ALL U.S. INVESTORSMay 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>May 9, 2023 | americanbankingnews.comWedbush Equities Analysts Cut Earnings Estimates for Magenta Therapeutics, Inc. (NASDAQ:MGTA)May 4, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RUTH, MGTA, OPCH, AMEDMay 4, 2023 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Magenta Therapeutics, Inc. MergerMay 4, 2023 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Magenta Therapeutics, Inc. MergerMay 4, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with DianthusMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 4, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with DianthusMay 3, 2023 | marketwatch.comMagenta Therapeutics Shares Drop 16% After Merger Deal With DianthusMay 3, 2023 | msn.comMagenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient DeathMay 3, 2023 | bizjournals.comStruggling Magenta scooped up by year-old biotech startupMay 3, 2023 | marketwatch.comMagenta Therapeutics to Merge With Dianthus TherapeuticsMay 3, 2023 | technews.tmcnet.comMGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to ShareholdersMay 3, 2023 | finance.yahoo.comMagenta Therapeutics and Dianthus Therapeutics Announce Merger AgreementMarch 31, 2023 | finance.yahoo.comMagenta Therapeutics Adopts Limited Duration Stockholder Rights PlanMarch 29, 2023 | americanbankingnews.comWedbush Analysts Increase Earnings Estimates for Magenta Therapeutics, Inc. (NASDAQ:MGTA)March 28, 2023 | americanbankingnews.comMagenta Therapeutics, Inc. (NASDAQ:MGTA) to Post FY2025 Earnings of $0.02 Per Share, HC Wainwright ForecastsMarch 28, 2023 | americanbankingnews.comMagenta Therapeutics, Inc. (NASDAQ:MGTA) Receives $3.67 Average PT from AnalystsMarch 27, 2023 | finance.yahoo.comIs Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans?March 26, 2023 | americanbankingnews.comMagenta Therapeutics' (MGTA) Neutral Rating Reiterated at WedbushMarch 24, 2023 | markets.businessinsider.comEQS-News: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of businessMarch 24, 2023 | markets.businessinsider.comMagenta Therapeutics (MGTA) Receives a Hold from H.C. WainwrightMarch 17, 2023 | seekingalpha.comMGTA Magenta Therapeutics, Inc.March 1, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Magenta Therapeutics (MGTA) with Neutral RecommendationFebruary 9, 2023 | finance.yahoo.comMagenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns LoomsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGTA Company Calendar Last Earnings11/04/2021Today5/29/2023Next Earnings (Estimated)5/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 201-2700FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+212.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.64% Return on Assets-58.09% Debt Debt-to-Equity RatioN/A Current Ratio13.95 Quick Ratio13.95 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book0.37Miscellaneous Outstanding Shares60,650,000Free Float53,638,000Market Cap$38.82 million OptionableNot Optionable Beta2.09 Key ExecutivesStephen Frank MahoneyPresident, Chief Financial & Operating OfficerLisa M. OlsonChief Scientific Officer & Head-ResearchCindy DriscollSenior Vice President-FinanceCatherine MonaghanHead-Clinical Development OperationsThomas W. BeethamSecretary & Chief Legal OfficerKey CompetitorsVincerx PharmaNASDAQ:VINCSynlogicNASDAQ:SYBXMustang BioNASDAQ:MBIONeoleukin TherapeuticsNASDAQ:NLTXKala PharmaceuticalsNASDAQ:KALAView All CompetitorsInsiders & InstitutionsAtlas Venture Life Science Advisors LLCBought 315,162 shares on 5/16/2023Ownership: 6.252%RBF Capital LLCSold 90,600 shares on 5/16/2023Ownership: 0.414%Susquehanna International Group LLPBought 181,503 shares on 5/16/2023Ownership: 0.299%Two Sigma Advisers LPSold 96,446 shares on 5/15/2023Ownership: 0.254%Two Sigma Investments LPSold 94,752 shares on 5/15/2023Ownership: 0.151%View All Insider TransactionsView All Institutional Transactions MGTA Stock - Frequently Asked Questions Should I buy or sell Magenta Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MGTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGTA, but not buy additional shares or sell existing shares. View MGTA analyst ratings or view top-rated stocks. What is Magenta Therapeutics' stock price forecast for 2023? 5 Wall Street research analysts have issued 1-year price targets for Magenta Therapeutics' stock. Their MGTA share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 212.5% from the stock's current price. View analysts price targets for MGTA or view top-rated stocks among Wall Street analysts. How have MGTA shares performed in 2023? Magenta Therapeutics' stock was trading at $0.3950 at the beginning of 2023. Since then, MGTA stock has increased by 62.0% and is now trading at $0.64. View the best growth stocks for 2023 here. Are investors shorting Magenta Therapeutics? Magenta Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 408,800 shares, a decline of 56.0% from the April 30th total of 930,000 shares. Based on an average daily volume of 514,400 shares, the short-interest ratio is currently 0.8 days. Approximately 0.9% of the shares of the stock are sold short. View Magenta Therapeutics' Short Interest. When is Magenta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 29th 2023. View our MGTA earnings forecast. How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.03. What ETF holds Magenta Therapeutics' stock ? Harbor Disruptive Innovation ETF holds 40,742 shares of MGTA stock, representing 0.10% of its portfolio. What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP). When did Magenta Therapeutics IPO? (MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Magenta Therapeutics' stock symbol? Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA." Who are Magenta Therapeutics' major shareholders? Magenta Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (6.25%), TCW Group Inc. (1.24%), Acadian Asset Management LLC (1.01%), Renaissance Technologies LLC (0.65%), RBF Capital LLC (0.41%) and Susquehanna International Group LLP (0.30%). Insiders that own company stock include Bruce Booth, Kristen Stants and Rock Ventures Iv LP Third. View institutional ownership trends. How do I buy shares of Magenta Therapeutics? Shares of MGTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Magenta Therapeutics' stock price today? One share of MGTA stock can currently be purchased for approximately $0.64. How much money does Magenta Therapeutics make? Magenta Therapeutics (NASDAQ:MGTA) has a market capitalization of $38.82 million. The company earns $-76,460,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. How can I contact Magenta Therapeutics? Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.magentatx.com. The company can be reached via phone at (857) 201-2700 or via email at investor@magentatx.com. This page (NASDAQ:MGTA) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.